SEK 12.54
(-2.79%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | - SEK | -100.0% |
2022 | 10 Thousand SEK | 0.0% |
2021 | - SEK | 0.0% |
2020 | - SEK | 0.0% |
2019 | - SEK | -100.0% |
2018 | 111.34 Thousand SEK | -85.63% |
2017 | 774.96 Thousand SEK | 484.11% |
2016 | 132.67 Thousand SEK | -10.39% |
2015 | 148.05 Thousand SEK | -34.56% |
2014 | 226.25 Thousand SEK | 50973.81% |
2013 | 443.00 SEK | 0.0% |
2012 | - SEK | -100.0% |
2011 | 1.00 SEK | -91.67% |
2010 | 12.00 SEK | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | - SEK | 0.0% |
2024 Q1 | - SEK | 0.0% |
2023 FY | - SEK | -100.0% |
2023 Q2 | - SEK | 0.0% |
2023 Q1 | - SEK | 0.0% |
2023 Q3 | - SEK | 0.0% |
2023 Q4 | - SEK | 0.0% |
2022 Q1 | - SEK | 0.0% |
2022 FY | 10 Thousand SEK | 0.0% |
2022 Q4 | - SEK | -100.0% |
2022 Q3 | 10 Thousand SEK | 0.0% |
2022 Q2 | - SEK | 0.0% |
2021 Q2 | - SEK | 0.0% |
2021 FY | - SEK | 0.0% |
2021 Q1 | - SEK | 0.0% |
2021 Q4 | - SEK | 0.0% |
2021 Q3 | - SEK | 0.0% |
2020 Q2 | - SEK | 0.0% |
2020 Q1 | - SEK | 0.0% |
2020 Q3 | - SEK | 0.0% |
2020 Q4 | - SEK | 0.0% |
2020 FY | - SEK | 0.0% |
2019 Q2 | - SEK | 0.0% |
2019 Q4 | - SEK | 0.0% |
2019 Q3 | - SEK | 0.0% |
2019 FY | - SEK | -100.0% |
2019 Q1 | - SEK | -100.0% |
2018 FY | 111.34 Thousand SEK | -85.63% |
2018 Q4 | 39.5 Thousand SEK | 0.0% |
2018 Q3 | - SEK | 0.0% |
2018 Q2 | - SEK | 0.0% |
2018 Q1 | - SEK | -100.0% |
2017 Q3 | 111 Thousand SEK | 0.0% |
2017 FY | 774.96 Thousand SEK | 484.11% |
2017 Q1 | 49.99 Thousand SEK | 0.0% |
2017 Q2 | - SEK | -100.0% |
2017 Q4 | 312.97 Thousand SEK | 181.96% |
2016 Q1 | 66.01 Thousand SEK | 0.0% |
2016 FY | 132.67 Thousand SEK | -10.39% |
2016 Q4 | - SEK | -100.0% |
2016 Q3 | 66.65 Thousand SEK | 0.0% |
2016 Q2 | - SEK | -100.0% |
2015 Q1 | 80.44 Thousand SEK | -57.17% |
2015 FY | 148.05 Thousand SEK | -34.56% |
2015 Q4 | - SEK | -100.0% |
2015 Q3 | 4918.00 SEK | -84.95% |
2015 Q2 | 32.68 Thousand SEK | -59.37% |
2014 FY | 226.25 Thousand SEK | 50973.81% |
2014 Q3 | - SEK | 0.0% |
2014 Q2 | - SEK | 0.0% |
2014 Q4 | 187.83 Thousand SEK | 0.0% |
2014 Q1 | - SEK | 0.0% |
2013 FY | 443.00 SEK | 0.0% |
2012 FY | - SEK | -100.0% |
2011 FY | 1.00 SEK | -91.67% |
2010 FY | 12.00 SEK | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Acarix AB (publ) | 6.24 Million SEK | 100.0% |
ADDvise Group AB (publ) | 1.37 Billion SEK | 100.0% |
ADDvise Group AB (publ) | 1.37 Billion SEK | 100.0% |
Arcoma AB | 163.01 Million SEK | 100.0% |
Bactiguard Holding AB (publ) | 203.99 Million SEK | 100.0% |
BICO Group AB (publ) | 2.23 Billion SEK | 100.0% |
Boule Diagnostics AB (publ) | 571.32 Million SEK | 100.0% |
CellaVision AB (publ) | 677.29 Million SEK | 100.0% |
Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | 100.0% |
Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | 100.0% |
C-Rad AB (publ) | 424.61 Million SEK | 100.0% |
Duearity AB (publ) | 1.65 Million SEK | 100.0% |
Dignitana AB (publ) | 86.06 Million SEK | 100.0% |
Episurf Medical AB (publ) | 10.3 Million SEK | 100.0% |
Getinge AB (publ) | 31.82 Billion SEK | 100.0% |
Iconovo AB (publ) | 7.07 Million SEK | 100.0% |
Integrum AB (publ) | 104.11 Million SEK | 100.0% |
Luxbright AB (publ) | 854.69 Thousand SEK | 100.0% |
Mentice AB (publ) | 273.61 Million SEK | 100.0% |
OssDsign AB (publ) | 112.15 Million SEK | 100.0% |
Paxman AB (publ) | 210.11 Million SEK | 100.0% |
Promimic AB (publ) | 37.07 Million SEK | 100.0% |
Qlife Holding AB (publ) | 244 Thousand SEK | 100.0% |
SciBase Holding AB (publ) | 23.24 Million SEK | 100.0% |
ScandiDos AB (publ) | 60.42 Million SEK | 100.0% |
Sectra AB (publ) | 2.96 Billion SEK | 100.0% |
Sedana Medical AB (publ) | 153.86 Million SEK | 100.0% |
Senzime AB (publ) | 35.75 Million SEK | 100.0% |
SpectraCure AB (publ) | 318 Thousand SEK | 100.0% |
Stille AB | 294.89 Million SEK | 100.0% |
Vitrolife AB (publ) | 3.51 Billion SEK | 100.0% |
Xvivo Perfusion AB (publ) | 597.54 Million SEK | 100.0% |